Affordable Access

deepdyve-link
Publisher Website

Ivor Lewis esophagogastrectomy for esophageal cancer

Authors
  • Visbal, Antonio L
  • Allen, Mark S
  • Miller, Daniel L
  • Deschamps, Claude
  • Trastek, Victor F
  • Pairolero, Peter C
Type
Published Article
Journal
The Annals of Thoracic Surgery
Publisher
Elsevier
Publication Date
Jan 01, 2001
Accepted Date
Feb 22, 2001
Volume
71
Issue
6
Pages
1803–1808
Identifiers
DOI: 10.1016/S0003-4975(01)02601-7
Source
Elsevier
Keywords
License
Unknown

Abstract

Background. To examine the efficacy of the Ivor Lewis esophagogastrectomy for esophageal carcinoma prior to the widespread use of preoperative chemotherapy and irradiation, we reviewed our experience. Methods. We reexamined the cases of 220 consecutive patients who underwent an Ivor Lewis esophagogastrectomy for esophageal cancer from January 1992 through December 1995. Results. There were 196 men (89.1%) and 24 women. Median age was 65 years (range, 29 to 85 years). The results of pathological study showed adenocarcinoma in 188 patients (85.5%), squamous cell carcinoma in 31 (14.1%), and leiomyosarcoma in 1 patient (0.5%). Postsurgical staging was as follows: stage 0 in 10 patients, stage I in 19, stage IIa in 38, stage IIb in 28, stage III in 111, and stage IV in 14. The operative mortality rate was 1.4% (3 patients), and complications occurred in 83 patients (37.7%). Follow-up was 98.6% complete. Median survival for operative survivors was 1.9 years (range, 32 days to 8.7 years). The overall 5-year survival rate was 25.2%; it was 80% for patients in stage 0, 94.4% for those in stage I, 36.0% for those in stage IIa, 14.3% for patients in stage IIb, 10% for those in stage III and 0% for patients in stage IV. Conclusions. Ivor Lewis esophagogastrectomy for esophageal cancer is a safe operation. Long-term survival is stage dependent. The low survival associated with advanced cancers should stimulate the search for effective neoadjuvant therapy.

Report this publication

Statistics

Seen <100 times